Long-term faricimab treatment for DME provides sustained efficacy and a safety profile consistent with phase 3 trials for at least 4 years, study shows.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results